The Procter & Gamble Company vs F. Hoffmann-La Roche AG: Strategic Comparison

This in-depth comparison examines The Procter & Gamble Company and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching The Procter & Gamble Company on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between The Procter & Gamble Company and F. Hoffmann-La Roche AG is widest.

On the headline numbers, The Procter & Gamble Company reports annual revenue of $84.3B against $77.2B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $390.0B and $327.5B. The Procter & Gamble Company is headquartered in United States and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.

The Procter & Gamble Company: P&G does not just sell household products; it helped invent the operating system for modern consumer goods. The 1931 brand management model, the proof-led advertising style of Ivory, the technical innovation behind Tide and Pampers, and the focused brand portfolio all still shape how the company competes.

F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.

The Procter & Gamble Company and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between The Procter & Gamble Company and F. Hoffmann-La Roche AG.

The Procter & Gamble Company business model: P&G makes money by selling branded daily-use consumer products across fabric care, home care, baby care, feminine care, family care, beauty, grooming, and health care. The model depends on product superiority, marketing, retail execution, premiumization, productivity, and repeat purchase.

F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of The Procter & Gamble Company stack up against those of F. Hoffmann-La Roche AG.

The Procter & Gamble Company competitive advantage: P&G advantage is the combination of trusted brands, R&D, retail execution, manufacturing scale, category management, and a portfolio concentrated in daily-use categories where repeat purchase matters.

F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.

Future prospects matter as much as current results. The growth strategies below explain how The Procter & Gamble Company and F. Hoffmann-La Roche AG each plan to expand from here.

The Procter & Gamble Company growth strategy: P&G strategy centers on product superiority, brand investment, productivity, digital commerce, supply-chain efficiency, portfolio focus, and selective reinvention of the company for the next consumer goods cycle.

F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.

A closer look at the financial trajectory of The Procter & Gamble Company and F. Hoffmann-La Roche AG rounds out the comparison.

The Procter & Gamble Company: P&G reported $84.284 billion of FY2025 net sales, compared with $84.039 billion in FY2024 and $82.006 billion in FY2023. Net earnings were $15.974 billion in FY2025. P&G had approximately 109,000 employees as of June 30, 2025.

F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.